Praxis
NASDAQ: PRAXBoston, US · Founded 2015 · 293 employees on LinkedIn · 14 known investors
Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy. Its portfolio uses both small molecule (Cerebrum) and antisense oligonucleotide (Solidus) platforms informed by human genetics and translational science.</parameter> <parameter name="founders">[]
Founders & leadership
Praxis was founded in 2015 by Steve Petrou.
SP
Steve PetrouinFounder · Chief Scientific Officer
KR
Kiran ReddyinExecutive
MS
Marcio SouzainPresident and CEO
Board
NG
Nicholas G. GalakatosBoard director
Investors · 14
Avoro Capital AdvisorsNew York
Capria VenturesBengaluru · $300K – $1M
OCV PartnersLos Angeles
Alameda Researchreported · 2 sourcesCentral and Western · $1.3M – $35M
APOLLO PROJECTSreportedSan Francisco
Blackstonereported
ClarusreportedCambridge
Norwest Venture Partnersreported · 2 sourcesMenlo Park · $10M – $30M
Novo HoldingsreportedCopenhagen · $1.1M – $54M
Paradigm CapitalreportedToronto
Robot VenturesreportedBeaverton · $100K – $1M
Three Arrows Capitalreported · 2 sources
Vida Venturesreported · 2 sourcesLos Angelesvia Stefan Vitorovic · board
Winklevoss CapitalreportedNew York · $100K – $5M
Funding
SEC filings, press & company announcements$31.9M disclosed across 3 of 5 rounds · 2016–2024
- Undisclosed amountSeries AMar 2022
Alameda Research, Apollo Projects, Paradigm Capital, Robot Ventures, Three Arrows Capital, Winklevoss Capital
Source ↗
▶$10MraisedJun 2019 · 5 investors · PharmaceuticalsRule 506(b)
▶$10MraisedJun 2019 · 5 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- KIRAN REDDYExecutive Officer, Director
- NICHOLAS GALAKATOSDirector
- THOMAS DYRBERGDirector
- STEFAN VITOROVICDirector
- STUART CHAFFEEExecutive Officer
- WILLIAM YOUNGDirector
- PAUL MEDEIROSDirector
- ARI BRETTMANDirector
- GREGORY NORDENDirector
- ALFRED SANDROCKDirector
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$18.8MraisedMar 2018 · 6 investors · PharmaceuticalsRule 506(b)
▶$18.8MraisedMar 2018 · 6 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- William D. YoungDirector
- Alfred Sandrock, Jr.Director
- Nicholas G. GalakatosDirector
- Stuart ChaffeeExecutive Officer
- Kiran ReddyExecutive Officer, Director
- Offering amount
- $46.4M
- Amount sold
- $18.8M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$3.1MraisedNov 2016 · 2 investors · PharmaceuticalsRule 506(b)
▶$3.1MraisedNov 2016 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas G. GalakatosDirector
- Kiran ReddyExecutive Officer, Director
- Offering amount
- $7.7M
- Amount sold
- $3.1M
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$796.1Mvaluation at IPOMay 2021 · $18.25/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances - Simply Wall St Newssimplywall.st · Aug 2026Frequently asked questions
- What does Praxis do?
- Praxis Precision Medicines is a central nervous system precision neuroscience biopharmaceutical company developing therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance, with a pipeline spanning movement disorders and epilepsy. Its portfolio uses both small molecule (Cerebrum) and antisense oligonucleotide (Solidus) platforms informed by human genetics and translational science.</parameter> <parameter name="founders">[]
- Who founded Praxis?
- Praxis was founded by Steve Petrou in 2015.
- Who are Praxis's investors?
- Praxis's investors include Avoro Capital Advisors, Capria Ventures, OCV Partners, Alameda Research, APOLLO PROJECTS, Blackstone, Clarus, Norwest Venture Partners and 6 more.
- How much funding has Praxis raised?
- Praxis has disclosed $31.9M raised across 3 of its 5 known rounds.
- Where is Praxis headquartered?
- Praxis is headquartered in Boston, US.